Site updated at Wednesday, 22 June 2016

Living with Dementia

Transdermal Rivastigmine

Drug Patch Gets OK for Severe Alzheimer’s

The FDA has expanded the indication for transdermal rivastigmine to include patients with severe Alzheimer’s disease.

The approval means that the transdermal agent is indicated for use in any Alzheimer’s patient, irrespective of disease stage or severity. The expanded indication is the first of its type for any Alzheimer’s drug, according to a statement… Drug Patch Gets OK for Severe Alzheimer’s   


genetic evidence1 - amyloidosis1 - diet high in carbohydrates1 - gastrointestinal disorders1 - healthy diet1 - invisible disease1 - reducing anxiety1 - bapineuzumab1 - prostate cancer1 - alzheimer's genes1 - motor coordination1 - amyloid beta Αβ plaques1 - mental faculties2 - risk factors for dementia1 - late-onset alzheimers disease1 - frontotemporal dementia signs1 - pomegranate1 - stages of atherosclerosis1 - progression of alzheimer's disease1 - vascular damage1 - parkinson's disease protein1 - esquirol1 - sign of alzheimer's1 - physical weakness1 - magnetic resonance imaging3 - α-synuclein protein2 - bmi2 - sleep loss1 - mediterranean and dash1 - personal care1 -